Abs 457 #ACR21 @rheumnow Exciting work by @alhkim and colleagues on SARS-CoV-2 Vaccination in CID patients - Most (90%) developed Ab response but with reduced titers - GC users including some low dose mounted low responses - TNFi reduced in vitro neutralization of delta variant https://t.co/fJxnKmbccc

Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?

#ClinicalPearl. During Q&A of abst#0457 Kim A, et al plenary at #ACR2021 #ACR21 Dr Kim said with 3rd #COVIDvaccination dose the pts who had little or no response to spike protein DID mount a response. 3rd dose in vulnerable pts works #ACRBest @RheumNow

The good news: Most (around 90%) of people with chronic #inflammatory disease produced antibodies after the #COVID19 vaccine, but it was reduced compared to that of generally healthy people. #ACR21 #Plenary @alhkim https://t.co/KdWtIuuOtA

plenary I. #ACR21 Interesting data with the delta variant from @alhkim https://t.co/oUCOXSc9wA

@alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of poor response BCDT >> MMF >> GCC > MTX/AZA/JAKi/TNFi > immunocompetent. Abstr#0457 #ACR21 @RheumNow https://t.co/lf8cAEWGXf

Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Rituxan: ⬆️ exposure to RTX over time, ⬇️ IgG levels prior to RTX, short interval btw RTX course & BNT162b2 vacc. RA highest&ANCA-vasculitis lowest probability for a + response. https://t.co/DsrJBlNvr7

#ACR21 Abst#0457: #COVID19 Vaccine Responses In Patients w Autoimmune Diseas ⭐️Prosp observ: pre-vax▶️5 mo. ⭐️ 90% +Ab responses, but ⬇️ titer ⭐️MMF 21x⬇️ titer, MTX 4.4x⬇️, AZA 3.5⬇️ ⭐️BCDT: 58, JAK: 2.6, TNF 2.3 ⭐️GC ⬇️ even on <5mg! https://t.co/BGU4CP9M0s @Rheumnow #ACRbest https://t.co/7QhsTGTwnZ

• https://bit.ly/3BPavft

#ACR21 Plenary Abs#0457 @alhkim #COVaRiPAD study: 👉Patients with inflammatory diseases on #immunosuppression have impaired #SARSCoV2 immunity post-vaccine 👉#Steroids, MMF & B cell depletion therapy more severely affect responses 👉https://t.co/7qTABcpm0h @RheumNow #ACRBest https://t.co/EfuHjh3vw5

• Immunosuppression Attenuates Antibody and Neutralization Titers in Patients wit…

COVID-19 mRNA vaccination immunogenicity (vs immunocompetent): TNFi: 2.3x reduction JAKi: 2.6x AZA: 3.5x MTX: 4.4x steroids: 9x (but confounded by other meds) MMF/MPA: 21x B cell depleting: 57.7x (but 6m gap probably helps) amazing work led by @alhkim #ACR21 ABST0457 @RheumNow https://t.co/cl5vBpNzvQ